FINWIRES · TerminalLIVE
FINWIRES

Visa Raises Fiscal 2026 Growth Outlook Following Second-Quarter Beat

作者

-- Visa (V) shares rose early Wednesday after the payments giant lifted its full-year growth outlook and reported better-than-expected fiscal second-quarter results.

The company now anticipates per-share adjusted earnings to increase by low-teens and adjusted revenue to rise by low-double-digit to low-teens, each on constant-dollar bases, for fiscal 2026, it said in a late Tuesday earnings presentation. It previously estimated both metrics to grow by low-double-digits, respectively.

The current consensus on FactSet is for non-GAAP EPS of $12.98 and sales of $45.05 billion for the fiscal year. The stock advanced 4.5% in the most recent premarket activity.

The increased revenue growth guidance reflects the company's "strong year-to-date performance" and current assumptions on "drivers, incentives, volatility and expected higher value-added services revenue growth, which incorporates the increased enthusiasm from our clients for the upcoming FIFA World Cup," Chief Financial Officer Christopher Suh said during an earnings call, according to a FactSet transcript.

Visa continues to expect broader consumer spend stability from a macro perspective, although the conflict in the Middle East has introduced uncertainty in the short term, especially related to cross-border travel spend in the Central and Eastern Europe, Middle East and Africa region, according to Suh.

The company forecasts improvements in inbound travel in the US and Latin America due to the 2026 FIFA World Cup, Suh told analysts.

For the three-month period ended March, adjusted EPS increased to $3.31 from $2.76 a year earlier, ahead of the Street's view for $3.10. Revenue rose 17% to $11.23 billion, topping the average analyst estimate of $10.75 billion. On a constant-dollar basis, revenue advanced 16% on a yearly basis.

"Consumer spending remained resilient, and our strategy and innovations fueled strong performance in consumer payments, commercial and money movement solutions and value-added services," Chief Executive Ryan McInerney said in a statement.

Visa's cross-border volume, excluding transactions within Europe, rose 11% on a constant-dollar basis. Payments volume grew 9% year over year in constant dollars, with the US logging a gain of 8%, according to Suh. Payments volume moved 10% higher in international markets, Suh said on the call.

Service revenue increased 13% to $4.98 billion while data processing revenue jumped 18% to $5.54 billion. International transaction revenue inclined 10% to $3.63 billion. Other revenue soared 41%, primarily driven by growth in advisory and other value-added services, especially marketing services revenue, as well as pricing, Suh told analysts.

For the ongoing three-month period, Visa expects adjusted EPS and net revenue to grow by mid-to-high single digits and by low double digits, respectively, in constant dollar terms. The Street is looking for non-GAAP EPS of $3.20 and sales of $11.24 billion.

相關文章

Australia

Ryde與VinaTaxi簽署諒解備忘錄,探索越南市場機會

Ryde集團(RYDE)週三宣布,已與VinaTaxi簽署諒解備忘錄,共同探索在越南的戰略合作機會。 該公司表示,合作探索的領域包括在VinaTaxi的計程車車隊中部署Ryde的平台,以及開發電動摩托車出行生態系統。Price: $1.20, Change: $+0.02, Percent Change: +1.61%

$RYDE
Australia

Emergent BioSolutions 簽署價值 5000 萬美元的合同,為 SAB Biotherapeutics 的領先項目提供支持

Emergent BioSolutions (EBS) 週三宣布,已與 SAB Biotherapeutics (SABS) 簽署一項價值 5000 萬美元的多年期協議,以推進 SAB-142 的臨床開發,該藥物用於治療自身免疫性 1 型糖尿病。 根據協議,其中 3,600 萬美元的款項取決於未來的監管審批和後續里程碑的達成情況。 Emergent BioSolutions 表示,將提供符合現行良好生產規範 (cGMP) 的端到端開發和生產服務。Price: $8.17, Change: $-0.07, Percent Change: -0.79%

$EBS$SABS
Australia

Immunome公司提交了基於3期臨床試驗數據的Varegacestat新藥申請。

Immunome(IMNM)週三宣布,已向美國食品藥物管理局(FDA)提交了新藥申請,申請上市的藥物為varegacestat,一種用於治療成人纖維瘤的在研口服藥物。 該公司表示,此次申請基於積極的3期RINGSIDE試驗結果,結果顯示與安慰劑相比,varegacestat顯著改善了患者的無進展生存期,降低了84%的疾病進展或死亡風險,客觀緩解率達到56%。 該公司補充說,試驗的詳細數據將在2026年美國臨床腫瘤學會(ASCO)年會上發表。 Immunome股價週三下跌2.7%。Price: $23.18, Change: $-0.53, Percent Change: -2.24%

$IMNM